{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:03:26Z","timestamp":1780355006281,"version":"3.54.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T00:00:00Z","timestamp":1537747200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40259-018-0307-0","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T13:07:21Z","timestamp":1537794441000},"page":"507-510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["SB5: An Adalimumab Biosimilar"],"prefix":"10.1007","volume":"32","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,24]]},"reference":[{"key":"307_CR1","unstructured":"European Medicines Agency. Imraldi 40 mg solution for injection: summary of product characteristics. 2017. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 4 July 2018."},{"key":"307_CR2","unstructured":"Lee N, Kim M, Lee JAJ, et al. Biosimilarity between Humira and the biosimilar candidate SB5 in product quality [abstract no. 2495]. In: ACR\/ARHP annual meeting; 2017."},{"key":"307_CR3","unstructured":"European Medicines Agency. CHMP assessment report: imraldi (adalimumab biosimilar). 2017. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 4 July 2018."},{"issue":"6","key":"307_CR4","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/jcpt.12583","volume":"42","author":"D Shin","year":"2017","unstructured":"Shin D, Lee Y, Kim H, et al. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. J Clin Pharm Ther. 2017;42(6):672\u20138.","journal-title":"J Clin Pharm Ther."},{"issue":"1","key":"307_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/art.40336","volume":"70","author":"ME Weinblatt","year":"2018","unstructured":"Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2018;70(1):40\u20138.","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"307_CR6","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/art.40444","volume":"70","author":"ME Weinblatt","year":"2018","unstructured":"Weinblatt ME, Baranauskaite A, Dokoupilova E, et al. Switching from reference adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis: fifty-two-week phase III randomized study results. Arthritis Rheumatol. 2018;70(6):832\u201340.","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"307_CR7","first-page":"878","volume":"44","author":"M Genovese","year":"2017","unstructured":"Genovese M, Weinblatt M, Keystone E, et al. Impact of anti-drug antibodies on efficacy and safety up to week 24 from a phase III study comparing SB5 (an adalimumab biosimilar) with reference adalimumab in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy [abstract no. 48]. J Rheumatol. 2017;44(6):878.","journal-title":"J Rheumatol."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-018-0307-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0307-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0307-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T23:42:09Z","timestamp":1569282129000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-018-0307-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,24]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["307"],"URL":"https:\/\/doi.org\/10.1007\/s40259-018-0307-0","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,24]]},"assertion":[{"value":"24 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. James Frampton is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}